Genprex, Inc. (GNPX) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Genprex, Inc.

GNPX

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

Biotechnology

Next Earning date - 08 Aug 2025

Biotechnology

Next Earning date - 08 Aug 2025

0.28USD

0.01 ( 4.25%)

Market Closed (as of May 23, 20:00 EDT)

Relative Strenght

Volume Buzz

-87%

Earning Acce

Yes

Dist 52w H.

93%

Overview Chart

Quote Panel

Updated May 24, 2025

1W 1.85 % 1M -3.44 % 3M -25.23 % 1Y -87.03 %

Key Metrics

Market Cap
7.65M
Shares Outstanding
27.82M
Share in Float
27.06M
Dividende
0

Earning Date
08 Aug 2025
Price Target
0.275
Average Volume
4.44M
Beta
-0.385

Range
0.215-4.09
Industry
Biotechnology
Website
https://www.genprex.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

771.56x

P/S Ratio

1.09x

P/B Ratio

0.0

Debt/Equity

-192687.5%

Net Margin

$-1.7

EPS

How GNPX compares to sector?

P/E Ratio

Fundamentals

Relative Strength

GNPX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$1.15

-342%

2026-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-6.00
vs -4.40

Q3.23

N/A

-5.20
vs -5.20

Q4.23

N/A

-3.96
vs -0.12

Q1.24

N/A

-3.69
vs -6.00

Q2.24

N/A

-3.00
vs -6.00

Q3.24

N/A

-1.23
vs -5.20

Q4.24

N/A

-1.15
vs -3.96

Q1.25

N/A

-0.26
vs -3.69

Q2.25

N/A

-0.42
vs -3.00

Q3.25

N/A

-0.25
vs -1.23

Sales Growth

YoY

Current

Estimates

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

23.2K vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-57%

9.9K vs 23.2K

Q1.25

NA vs NA

Return on Equity

QoQ

Q2.23

-66%

-0.66
vs -0.50

Q3.23

-63%

-0.63
vs -0.66

Q4.23

-80%

-0.80
vs -0.63

Q1.24

-68%

-0.68
vs -0.80

Q2.24

-149%

-1.49
vs -0.68

Q3.24

-259%

-2.59
vs -1.49

Q4.24

-267%

-2.67
vs -2.59

Q1.25

-103%

-1.03
vs -2.67

Institutionnal Ownership

QoQ

Q1.22

54
vs 51

Q2.22

43
vs 54

-20%

Q3.22

46
vs 43

Q4.22

52
vs 46

13%

Q1.23

40
vs 52

-23%

Q2.23

39
vs 40

-2%

Q3.23

38
vs 39

-3%

Q4.23

33
vs 38

-13%

Earnings Growth

Latest News

prnewswire.com

7 hours ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

prnewswire.com

7 hours ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

prnewswire.com

7 hours ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

prnewswire.com

7 hours ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

prnewswire.com

7 hours ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

prnewswire.com

8 hours ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Company Description

0.28USD

N/A

771.56x

1.09x

0.0

-192687.5%

$-1.7

$1.15

Earnings Growth

Latest News

N/A

771.56x

1.09x

0.0

-192687.5%

$-1.7

Company Description

0.28USD